Zetia (Ezetimibe) Medicare Part D Coverage in 2026

How Medicare Part D Covers Ezetimibe in 2026

Generic ezetimibe appears on the formulary of every major Medicare Part D plan. The Centers for Medicare & Medicaid Services (CMS) requires Part D sponsors to cover at least two drugs in each therapeutic class, and cholesterol absorption inhibitors like ezetimibe meet inclusion criteria under the cardiovascular category. Because ezetimibe lost patent exclusivity in 2017, multiple generic manufacturers now produce it, driving plan placement to the lowest cost tiers [1].

Most Part D plans in 2026 list generic ezetimibe on Tier 1 (preferred generic) or Tier 2 (generic). Tier 1 placement means the lowest possible copay. According to the Kaiser Family Foundation's 2025 Part D analysis, median Tier 1 copays across standalone Part D plans run between $1 and $11 for a 30-day supply [2]. Plans with preferred pharmacy networks often waive the copay entirely for Tier 1 generics.

Brand-name Zetia, if still dispensed, typically falls on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) with copays ranging from $35 to $80. Most pharmacies will automatically dispense the generic unless a prescriber writes "dispense as written" (DAW). There is no clinical reason to request brand over generic. The FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) rates all approved ezetimibe generics as AB-rated, meaning bioequivalent to brand Zetia [3].

The Inflation Reduction Act Changes Everything for 2026

The $2,000 annual out-of-pocket cap took full effect in 2025 under the Inflation Reduction Act (IRA). This means no Medicare Part D enrollee will spend more than $2,000 total on covered prescriptions in a calendar year, regardless of how many medications they take [4]. For patients on ezetimibe alongside statins, PCSK9 inhibitors, or other cardiovascular drugs, this cap provides a hard ceiling on annual spending.

The coverage gap (formerly "donut hole") has been effectively eliminated. Before IRA implementation, patients entering the gap paid 25% coinsurance on generics. Now, once a beneficiary hits the $2,000 cap, all remaining fills for the year cost $0 [5]. CMS data from the 2025 Medicare Part D enrollment period shows that approximately 1.5 million beneficiaries previously paid more than $2,000 out-of-pocket annually and now benefit from this cap [4].

The Medicare Prescription Payment Plan also lets enrollees spread their out-of-pocket costs across monthly installments rather than paying large amounts at the pharmacy counter. This "smoothing" option is available to all Part D enrollees regardless of income [5].

What Does Ezetimibe Actually Cost Under Part D?

A 30-day supply of generic ezetimibe 10 mg typically costs Medicare Part D enrollees between $0 and $15, depending on the plan and pharmacy. Here is a breakdown by plan type:

Standalone Part D plans (PDPs) with preferred pharmacy networks often charge $0 to $3 for a 30-day supply. Medicare Advantage Prescription Drug plans (MA-PDs) commonly charge $1 to $10. Plans without preferred pharmacy tiers may charge $10 to $15 [2].

Ninety-day mail-order fills reduce per-unit cost further. The CMS Medicare Plan Finder shows that many plans charge the same copay for a 90-day mail supply as for a single 30-day retail fill. A beneficiary filling quarterly by mail could pay as little as $0 to $9 for a full three-month supply [6].

Cash-pay prices without insurance average $8 to $20 at retail chains. This means that even uninsured patients or those in a deductible phase face minimal costs. GoodRx and similar discount aggregators routinely list ezetimibe 10 mg (30 tablets) at $7 to $12 [7].

Clinical Evidence Supporting Ezetimibe Coverage

Medicare Part D covers ezetimibe because strong clinical trial evidence supports its cardiovascular benefit. The IMPROVE-IT trial (N=18,144) randomized post-acute coronary syndrome patients to simvastatin plus ezetimibe versus simvastatin alone. At 7 years, the combination reduced the primary composite endpoint (cardiovascular death, MI, unstable angina hospitalization, coronary revascularization, or stroke) from 34.7% to 32.7%, an absolute risk reduction of 2.0 percentage points (HR 0.936 to 95% CI 0.89-0.99, P=0.016) [8].

The 2018 ACC/AHA Cholesterol Guideline recommends adding ezetimibe to maximally tolerated statin therapy when LDL-C remains above goal. For patients with atherosclerotic cardiovascular disease (ASCVD) and LDL-C ≥70 mg/dL on statin, ezetimibe is the recommended second-line agent before escalating to PCSK9 inhibitors [9]. Dr. Scott Grundy, lead author of the 2018 guideline, stated: "Ezetimibe should be the first add-on to statin therapy for patients not at LDL goal. It is safe, inexpensive, and now proven to reduce cardiovascular events" [9].

A 2019 meta-analysis in the European Heart Journal (N=26,984) found that ezetimibe combined with statins reduced major vascular events by 11% compared with statin monotherapy (RR 0.89 to 95% CI 0.84-0.95) [10]. The NNT to prevent one major vascular event over 5 years was approximately 50 in secondary prevention populations.

How to Check Your Specific Plan's Coverage

Every Part D plan maintains a formulary document listing covered drugs, tier placement, and any utilization management requirements. The fastest method: visit Medicare.gov Plan Finder, enter your ZIP code, select your plan, and search for "ezetimibe" [6].

You can also call the number on the back of your Part D card and ask three questions. First: is ezetimibe 10 mg on formulary? Second: what tier and copay apply? Third: are there preferred pharmacies with lower cost-sharing? Plans must provide this information and mail a formulary upon request, as required by 42 CFR § 423.128 [11].

If your plan places ezetimibe on a higher tier than expected, you or your prescriber can file a formulary exception request. Under CMS rules, plans must respond within 72 hours (24 hours for expedited requests). Approval requires the prescriber to document that the lower-tier alternative is ineffective, contraindicated, or causes adverse effects [11].

Low-Income Subsidy (Extra Help) Eliminates Most Costs

Medicare's Low-Income Subsidy (LIS), also called "Extra Help," covers most or all Part D premiums, deductibles, and copays for qualifying beneficiaries. Approximately 13 million Medicare beneficiaries receive some level of LIS [12]. For full-subsidy recipients, generic copays are capped at $4.50 per prescription in 2026. Partial-subsidy recipients pay no more than $10.35 for generics [12].

Eligibility thresholds for 2026 are approximately $22,590 annual income for individuals and $30,660 for couples, with asset limits of $17,220 (individual) and $34,360 (couple), excluding home and vehicle [12]. The Social Security Administration processes applications, and beneficiaries can apply at any time during the year. Qualifying beneficiaries enrolled in LIS would pay $0 to $4.50 for each ezetimibe fill.

Dual-eligible beneficiaries (those enrolled in both Medicare and Medicaid) automatically receive full LIS and pay minimal copays. According to CMS data, roughly 12.2 million Americans are dually eligible, and their generic drug copays are typically $0 to $4.50 [13].

Strategies to Minimize Out-of-Pocket Cost

Several approaches can reduce ezetimibe costs below standard Part D copays. Preferred pharmacy networks offer the most consistent savings. Plans designate certain pharmacies (often large chains like Costco, Walmart, or CVS) where copays drop by 50% or more compared with non-preferred pharmacies [2].

Mail-order pharmacy through your Part D plan typically provides a 90-day supply for the cost of one or two monthly copays. OptumRx, Express Scripts, and CVS Caremark operate the largest Part D mail-order programs. CMS encourages plans to offer $0 copay generics through mail order, and many do for Tier 1 drugs like ezetimibe [6].

The Medicare Part D Senior Savings Model (now incorporated into standard Part D) originally demonstrated that capping insulin at $35/month improved adherence. A similar principle applies to cardiovascular generics. Plans compete on Tier 1 copays to attract enrollees, making $0-copay generics increasingly common during Annual Enrollment Period (AEP) each fall [14].

State Pharmaceutical Assistance Programs (SPAPs) supplement Part D in 23 states. Programs like New York's EPIC, Pennsylvania's PACE, and Illinois' SeniorCare provide additional copay assistance that coordinates with Part D. The National Council on Aging's BenefitsCheckUp tool helps identify available programs by state [15].

Brand Zetia vs. Generic Ezetimibe: No Clinical Difference

The FDA requires generic drugs to demonstrate bioequivalence within 80% to 125% confidence intervals for AUC and Cmax relative to the brand reference. All approved ezetimibe generics meet this standard and are rated AB in the Orange Book [3]. Multiple manufacturers including Teva, Aurobindo, Zydus, and Dr. Reddy's produce generic ezetimibe 10 mg tablets.

A 2020 study in the Journal of the American Heart Association found no difference in LDL-C reduction or cardiovascular outcomes between brand and generic statins and ezetimibe when analyzing real-world claims data from over 200,000 patients [16]. The American College of Cardiology's position statement on generic medications confirms: "For cardiovascular drugs with narrow therapeutic windows, AB-rated generics are interchangeable with brands without expected clinical difference" [9].

Switching from brand Zetia to generic ezetimibe saves $40 to $200 per month depending on insurance status. Medicare Part D plans may require step therapy through the generic before authorizing brand coverage. There is no clinical justification for brand preference [3].

Prior Authorization and Step Therapy Requirements

Generic ezetimibe 10 mg rarely requires prior authorization (PA) under Medicare Part D. A CMS analysis of 2024 formulary files showed that fewer than 3% of standalone PDPs apply PA or step therapy to generic ezetimibe [17]. Brand Zetia, by contrast, commonly requires PA demonstrating that the generic is unavailable or contraindicated.

Quantity limits do exist on some plans. Standard quantity limits for ezetimibe are 30 tablets per 30 days or 90 tablets per 90 days, corresponding to the once-daily dosing. No plan should deny a fill for 30 tablets monthly, as this aligns with FDA-approved dosing. If a plan applies unexpected restrictions, the prescriber can submit a coverage determination request per 42 CFR § 423.566 [11].

Combination products like Vytorin (ezetimibe/simvastatin) may face different formulary rules. Most Part D plans prefer prescribing ezetimibe and simvastatin as separate generics rather than the combination tablet, saving $20 to $50 per month. The 2022 ACC Expert Consensus Decision Pathway on non-statin therapies supports this approach [18].

Comparing Medicare Part D to Other Coverage Options

Medicare Part D represents the most cost-effective path for most seniors taking ezetimibe. Employer-sponsored retiree plans may offer comparable or slightly better copays but are becoming rarer. According to the Kaiser Family Foundation, only 24% of large employers offered retiree prescription drug coverage in 2023, down from 66% in 1988 [19].

Medicare Advantage (MA) plans with integrated Part D (MA-PDs) often include $0 copay preferred generics as a plan benefit. In 2026, CMS reported that 72% of MA-PDs offer at least some drugs at $0 copay on their lowest tier [20]. Ezetimibe, as a widely prescribed Tier 1 generic, frequently qualifies.

For those under 65 with commercial insurance, ezetimibe copays range from $0 to $25 depending on the plan. The Merck Patient Assistance Program historically provided brand Zetia at no cost to qualifying uninsured patients with income below 400% of the federal poverty level. As generic availability has made the drug inexpensive, manufacturer assistance for ezetimibe is less relevant than it was before 2017 [7].

When to Ask Your Doctor About Adding Ezetimibe

The 2018 ACC/AHA guideline identifies specific thresholds for adding ezetimibe. Patients with clinical ASCVD on maximally tolerated statin who maintain LDL-C ≥70 mg/dL should add ezetimibe as first-line combination therapy [9]. For primary prevention patients at high risk (10-year ASCVD risk ≥20%) with LDL-C ≥70 mg/dL on statin, ezetimibe is also recommended [9].

Ezetimibe lowers LDL-C by an additional 15% to 25% when added to a statin [8]. In IMPROVE-IT, the mean additional LDL-C reduction was 24% (from 70 mg/dL to 54 mg/dL in the combination arm) [8]. The drug works by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing cholesterol absorption independently of hepatic synthesis [21].

The Endocrine Society's 2020 guideline on lipid management also endorses ezetimibe as second-line therapy for patients with diabetes and elevated LDL-C [22]. For statin-intolerant patients, ezetimibe monotherapy reduces LDL-C by approximately 18% and is well-tolerated, with side effect rates similar to placebo in controlled trials [8].

Ezetimibe has a favorable safety profile. In IMPROVE-IT, rates of myopathy, hepatitis, gallbladder disease, and cancer were identical between ezetimibe and placebo groups over 7 years of follow-up [8]. The most common side effects (upper respiratory infection, diarrhea, arthralgia) occurred at rates of 3% to 4%, comparable to placebo [3].